JP2014515595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515595A5 JP2014515595A5 JP2013556654A JP2013556654A JP2014515595A5 JP 2014515595 A5 JP2014515595 A5 JP 2014515595A5 JP 2013556654 A JP2013556654 A JP 2013556654A JP 2013556654 A JP2013556654 A JP 2013556654A JP 2014515595 A5 JP2014515595 A5 JP 2014515595A5
- Authority
- JP
- Japan
- Prior art keywords
- linker
- polypeptide
- composition
- amino acid
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 174
- 229920001184 polypeptide Polymers 0.000 claims description 111
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 111
- 239000000203 mixture Substances 0.000 claims description 87
- 150000001413 amino acids Chemical group 0.000 claims description 75
- 102000040430 polynucleotide Human genes 0.000 claims description 34
- 108091033319 polynucleotide Proteins 0.000 claims description 34
- 239000002157 polynucleotide Substances 0.000 claims description 34
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 20
- 239000004471 Glycine Substances 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 10
- MHJJUOJOAJLYBS-ZBRNBAAYSA-N (2s)-2-aminopropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound C[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 MHJJUOJOAJLYBS-ZBRNBAAYSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 108010091748 peptide A Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 208000005340 mucopolysaccharidosis III Diseases 0.000 claims 1
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449225P | 2011-03-04 | 2011-03-04 | |
| US61/449,225 | 2011-03-04 | ||
| PCT/US2011/041928 WO2011163652A2 (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
| US13/168,969 US20110318327A1 (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
| US13/168,969 | 2011-06-25 | ||
| USPCT/US2011/041928 | 2011-06-25 | ||
| PCT/US2012/027561 WO2012122042A2 (en) | 2011-03-04 | 2012-03-02 | Peptide linkers for polypeptide compositions and methods for using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016152698A Division JP6594833B2 (ja) | 2011-03-04 | 2016-08-03 | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515595A JP2014515595A (ja) | 2014-07-03 |
| JP2014515595A5 true JP2014515595A5 (enExample) | 2015-04-16 |
| JP6175372B2 JP6175372B2 (ja) | 2017-08-02 |
Family
ID=49165891
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556654A Active JP6175372B2 (ja) | 2011-03-04 | 2012-03-02 | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 |
| JP2016152698A Active JP6594833B2 (ja) | 2011-03-04 | 2016-08-03 | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 |
| JP2019111936A Pending JP2019150065A (ja) | 2011-03-04 | 2019-06-17 | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016152698A Active JP6594833B2 (ja) | 2011-03-04 | 2016-08-03 | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 |
| JP2019111936A Pending JP2019150065A (ja) | 2011-03-04 | 2019-06-17 | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2680879B1 (enExample) |
| JP (3) | JP6175372B2 (enExample) |
| CN (2) | CN106279433A (enExample) |
| AU (3) | AU2012225766B9 (enExample) |
| BR (1) | BR112013022557A2 (enExample) |
| CA (2) | CA3080181A1 (enExample) |
| WO (1) | WO2012122042A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| RU2680581C2 (ru) | 2012-11-27 | 2019-02-22 | Байомарин Фармасьютикал Инк. | Направленные терапевтические химерные белки лизосомальных ферментов и их применение |
| EP3193942B1 (en) | 2014-08-11 | 2020-03-25 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
| MA41022A (fr) | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
| US20220243210A1 (en) * | 2019-05-17 | 2022-08-04 | Ionis Pharmaceuticals, Inc. | Angiotensin ii type 1 receptor targeted oligonucleotides and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11508126A (ja) * | 1995-05-23 | 1999-07-21 | モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー | 多量体タンパク質 |
| CA2378924A1 (en) * | 1999-07-15 | 2001-01-25 | Howard A. Fields | Synthetic peptides immunoreactive with hepatitis a virus antibodies |
| US20040181830A1 (en) * | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| US7629309B2 (en) * | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| KR20050062572A (ko) * | 2002-10-01 | 2005-06-23 | 가부시키가이샤 디나벡크 겐큐쇼 | ＴＡＰ 활성의 저해에 의해 ＭＨＣ ｃｌａｓｓ Ⅰ에 의한외래 에피토프의 제시를 증강시키는 방법 |
| JP4493327B2 (ja) * | 2003-12-09 | 2010-06-30 | 三洋化成工業株式会社 | 細胞接着性ポリペプチド |
| JP4897792B2 (ja) * | 2005-04-20 | 2012-03-14 | ビロメッド カンパニー， リミテッド | 融合タンパク質の分離のための組成物および方法 |
| GB0511124D0 (en) * | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| GB0524987D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| GB0611463D0 (en) * | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
| EP3492488A1 (en) * | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| CN101186637B (zh) * | 2007-11-14 | 2011-09-14 | 中国科学院微生物研究所 | 抑制流感病毒感染的方法及其药物 |
| US8470771B2 (en) * | 2007-11-14 | 2013-06-25 | Institute Of Microbiology, Chinese Academy Of Sciences | Method and medicament for inhibiting the infection of influenza virus |
| US20110223147A1 (en) | 2008-05-07 | 2011-09-15 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| TWI496582B (zh) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| US8697654B2 (en) * | 2008-12-18 | 2014-04-15 | E I Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
| CN102365295A (zh) * | 2009-01-30 | 2012-02-29 | 阿德利夫股份有限公司 | 构象动力肽 |
| US20110318327A1 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
-
2012
- 2012-03-02 CA CA3080181A patent/CA3080181A1/en not_active Abandoned
- 2012-03-02 WO PCT/US2012/027561 patent/WO2012122042A2/en not_active Ceased
- 2012-03-02 AU AU2012225766A patent/AU2012225766B9/en active Active
- 2012-03-02 BR BR112013022557A patent/BR112013022557A2/pt not_active Application Discontinuation
- 2012-03-02 EP EP12754246.2A patent/EP2680879B1/en not_active Not-in-force
- 2012-03-02 CN CN201610670405.5A patent/CN106279433A/zh active Pending
- 2012-03-02 JP JP2013556654A patent/JP6175372B2/ja active Active
- 2012-03-02 CN CN201280020811.7A patent/CN103764162B/zh active Active
- 2012-03-02 CA CA2828966A patent/CA2828966C/en active Active
-
2016
- 2016-08-03 JP JP2016152698A patent/JP6594833B2/ja active Active
-
2017
- 2017-06-28 AU AU2017204405A patent/AU2017204405B2/en active Active
-
2019
- 2019-04-24 AU AU2019202865A patent/AU2019202865B2/en not_active Expired - Fee Related
- 2019-06-17 JP JP2019111936A patent/JP2019150065A/ja active Pending